Abstract:Objective To investigate retrospectively the efficacy of cyclosporine A (CsA) in the treatment of membranous lupus nephropathy (MLN).Methods Twenty-four patients with systemic lupus erythematosus ( SLE) and biopsy-proven MLN were treated with CsA in combination with prednisone. CsA was given at a starting dosage of 5 mg (.) kg(-1) (.) d(-1) for 3 months, with a 1mg (.) kg(-1) (.) d(-1) reduction every month and then maintained at a dosage of 2 mg (.) kg(-1) (.) d(-1). The dosage of oral prednisone differed from person to person according to levels of extra-renal activity. Clinical efficacy and adverse reactions were retrospectively analyzed. Complete remission was defined as having a urinary proteinuria level (Upr) of <0.4 g/d, and normal serum albumin and serum creatinine (SCr) levels, without SLE activity. Partial remission was defined as having a UPr decrement > 50% of baseline value and a serum albumin value of 30 - 35 g/L, without SLE activity. No response was defined as having a Upr decrement <50% of baseline value and >2.0 g/d, or as a deterioration of renal function, or as having active SLE.Results One patient could no longer undergo follow-up, and the other 23 patients were treated with CsA and followed up for 6 - 36 months (mean 16.8 +/- 8.4 months). The mean starting dosage of CsA was 4.7 +/- 0.5) mg (.) kg(-1) (.) d(-1) and the trough level of the whole blood CsA was 248 110) mug/L. Twelve patients (52.2%) achieved complete remission, 10 patients (43.3%) achieved partial remission after CsA treatment, and one patient showed no response. At different CsA treatment timepoint, the complete remission rates were 17.4% (3rd month), 21.7% (6th month), 40% (12th month), 88.9% (18th month) and 100% (24th month) respectively. SCr elevation, when within a normal limit was not observed in most patients during early CsA administration, and at the end of the follow-up all the patients had a normal SCr. Relapse occurred in 33.3% of the patients after withdrawing CsA for 4-24 months. No chronic CsA renal toxicity was observed in 4 patients who had a repeat renal biopsy after CsA treatment for 6-24 months.Conclusions CsA could be regarded as an effective therapy for patients with membranous lupus nephropathy, but its adverse effects, especially its nephrotoxicity, should be carefully monitored during CsA treatment.

Red Blood Cell Membrane Functionalized Biomimetic Nanoparticles for Systemic Lupus Erythematosus Treatment

Apoptotic Cell-Mimicking Gold Nanocages Loaded with LXR Agonist for Attenuating the Progression of Murine Systemic Lupus Erythematosus.

Biomimetic liposomes hybrid with erythrocyte membrane modulate dendritic cells to ameliorate systemic lupus erythematosus

A Novel Azathioprine Polysaccharide Nanoparticle Enhances the Efficacy of Systemic Lupus Erythematosus Therapy

Exploring pectin-casein micelles as novel carriers for oral drug delivery of artesunate in the treatment of systemic lupus erythematosus

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study

Lymph node targeting of cyclosporine ameliorates ocular manifestations in a mouse model of systemic lupus erythematosus (SLE) via PD-L1

Mesenchymal Stem Cell Membrane‐Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia‐Reperfusion Injury Prevention

Bio-inspired Adhesive Porous Particles with Human MSCs Encapsulation for Systemic Lupus Erythematosus Treatment

Amphiphilic Poly(L-Aspartic Acid) Copolymer Nanoparticles for Cyclosporine A Delivery

Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus

Engineered Cell Membrane Vesicles Expressing CD40 Alleviate System Lupus Nephritis by Intervening B Cell Activation

Biomimetic nanoparticles with cell-membrane camouflage for rheumatoid arthritis

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Cyclosporine A in Treatment of Membranous Lupus Nephropathy

A biomimetic adipocyte mesenchymal stem cell membrane-encapsulated drug delivery system for the treatment of rheumatoid arthritis

The Increased Efficacy and Decreased Nephrotoxicity of A Cyclosporine Liposome

MCP-1 and IL-4 Encapsulated Hydrogel Particles with Macrophages Enrichment and Polarization Capabilities for Systemic Lupus Erythematosus Treatment

Revolutionizing Rheumatoid Arthritis Therapy: Harnessing Cytomembrane Biomimetic Nanoparticles for Novel Treatment Strategies

Dexamethasone Loaded DNA Scavenger Nanogel for Systemic Lupus Erythematosus Treatment

Biomimetic nanoparticles: U937 cell membranes based core–shell nanosystems for targeted atherosclerosis therapy